Comparative Pharmacology
Head-to-head clinical analysis: MAGNESIUM SULFATE versus POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5 AND SODIUM CHLORIDE 0 225 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MAGNESIUM SULFATE versus POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5 AND SODIUM CHLORIDE 0 225 IN PLASTIC CONTAINER.
MAGNESIUM SULFATE vs POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Magnesium sulfate acts as a physiological calcium channel blocker. It inhibits calcium influx into presynaptic nerve terminals, reducing acetylcholine release at the neuromuscular junction and decreasing muscle contraction. It also antagonizes NMDA receptors and stabilizes neuronal membranes.
Potassium chloride (KCl) dissociates to K+ ions, which are essential for maintaining intracellular osmolarity, nerve impulse transmission, cardiac and skeletal muscle contraction, and acid-base balance. Dextrose 5% provides calories and may help prevent ketosis. Sodium chloride 0.225% provides sodium and chloride ions to maintain electrolyte balance.
IV: Loading dose 4-6 g over 20-30 minutes, followed by maintenance infusion 1-2 g/hour for seizure prophylaxis in severe preeclampsia/eclampsia. IM: 4-8 g deep IM initially, then 4 g every 4 hours as needed.
The typical adult dose is 10 mEq of potassium chloride (as 20 mL of 10 mEq/20 mL solution) administered intravenously at a rate not exceeding 10 mEq per hour, diluted in an appropriate IV fluid such as D5W or NS. For this product (10 mEq KCl in D5 0.225% NaCl), the entire container is infused at a rate to deliver potassium at 10 mEq/hour or slower, with continuous ECG monitoring.
Clinical Note
moderateMagnesium sulfate + Gatifloxacin
"The serum concentration of Gatifloxacin can be decreased when it is combined with Magnesium sulfate."
Clinical Note
moderateMagnesium sulfate + Rosoxacin
"The serum concentration of Rosoxacin can be decreased when it is combined with Magnesium sulfate."
Clinical Note
moderateMagnesium sulfate + Levofloxacin
"The serum concentration of Levofloxacin can be decreased when it is combined with Magnesium sulfate."
Clinical Note
moderateNone Documented
None Documented
Terminal elimination half-life approximately 4-6 hours in patients with normal renal function; prolonged to 12-24 hours or more in renal impairment, necessitating dose adjustment
Not applicable for intravenous potassium; rapid distribution and elimination with first-order kinetics; serum potassium half-life ~2-3 hours with normal renal function
Primarily renal (90-95% as unchanged drug); minor biliary/fecal (<5%)
Primarily renal (90-95% excreted unchanged in urine); minimal fecal (~5%)
Category C
Category A/B
Electrolyte
Electrolyte
Magnesium sulfate + Trovafloxacin
"The serum concentration of Trovafloxacin can be decreased when it is combined with Magnesium sulfate."